Anebulo Pharmaceuticals, Inc.
9:00 AM - 9:15 AM (EST), Monday, February 6, 2023 ・ Palace
Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse disorder. Its lead product candidate, ANEB-001, has completed dosing in a Phase 2 clinical trial (www.clinicaltrials.gov/ct2/show/NCT05282797) evaluating its utility in reversing the negative effects of acute cannabinoid intoxication. ANEB-001 is a competitive antagonist at the human cannabinoid receptor type 1 (CB1). For further information about Anebulo, please visit www.anebulo.com.
Ticker:
ANEB
Exchange:
Nasdaq
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
South Carolina
Company HQ Country:
United States
Year Founded:
Not Provided
Main Therapeutic Focus:
Pain Management
Lead Product in Development:
ANEB-001
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
